LLY

1,008.73

-1.37%↓

JNJ

242.5

-1.77%↓

ABBV

224.75

+0.24%↑

NVS

162.69

-0.47%↓

MRK

122.26

+0.39%↑

LLY

1,008.73

-1.37%↓

JNJ

242.5

-1.77%↓

ABBV

224.75

+0.24%↑

NVS

162.69

-0.47%↓

MRK

122.26

+0.39%↑

LLY

1,008.73

-1.37%↓

JNJ

242.5

-1.77%↓

ABBV

224.75

+0.24%↑

NVS

162.69

-0.47%↓

MRK

122.26

+0.39%↑

LLY

1,008.73

-1.37%↓

JNJ

242.5

-1.77%↓

ABBV

224.75

+0.24%↑

NVS

162.69

-0.47%↓

MRK

122.26

+0.39%↑

LLY

1,008.73

-1.37%↓

JNJ

242.5

-1.77%↓

ABBV

224.75

+0.24%↑

NVS

162.69

-0.47%↓

MRK

122.26

+0.39%↑

Home・Aktien・Pliant Therapeutics Inc

Pliant Therapeutics Inc

Geschlossen

1.28 2.4

Buy Sell

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

1.28

Max

1.28

Schlüsselkennzahlen
By Trading Economics
Einkommen	17M -26M
Angestellte	171
EBITDA	19M -23M

Dividenden
By Dow Jones
Nächstes Ergebnis	26. Feb. 2026

Marktstatistiken
By TradingEconomics
Marktkapitalisierung	-34M 68M
Vorheriger Eröffnungskurs	-1.12
Vorheriger Schlusskurs	1.28

Technischer Score

By Trading Central

Vertrauen

Very Strong Bearish Evidence

1.43 / 1.6 Unterstützung & Widerstand

Pliant Therapeutics Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

22. Feb. 2026, 23:55 UTC

Market Talk

Gold and Silver Rise Amid Renewed Trade Tensions -- Market Talk

22. Feb. 2026, 23:53 UTC

Market Talk

Japan Activity Data Set to Show Strength, Backed by Fiscal Spending -- Market Talk

22. Feb. 2026, 23:53 UTC

Market Talk

Key China Rates Likely to Be Held Steady for Now -- Market Talk

22. Feb. 2026, 23:51 UTC

Market Talk

Bank of Korea Set to Hold Fire as Inflation Steadies, Risks Linger -- Market Talk

22. Feb. 2026, 23:35 UTC

Market Talk

Oil Falls Amid Prospect That U.S. Strike on Iran Might Be Limited -- Market Talk

22. Feb. 2026, 23:21 UTC

Ergebnisse

Nickel Industries 2025 Adjusted Ebitda US$283.0 Million

22. Feb. 2026, 23:20 UTC

Ergebnisse

Nickel Industries 2025 Operating Profit US$126.4 Million

22. Feb. 2026, 23:19 UTC

Ergebnisse

Nickel Industries 2025 Revenue US$1.65 Billion, Down 5.5% On-Year

22. Feb. 2026, 23:19 UTC

Ergebnisse

Correct: Nickel Industries 2025 Net Loss US$57.1 Million, Down 66% On-Year

22. Feb. 2026, 23:18 UTC

Ergebnisse

Nickel Industries Won't Pay a Final Dividend

22. Feb. 2026, 23:16 UTC

Ergebnisse

Nickel Industries 2025 Net Loss A$57.1 Million, Down 66% On-Year

22. Feb. 2026, 21:35 UTC

Ergebnisse

Ampol Expects to Start Commissioning of Ultra Low Sulfur Fuels Project in 2Q

22. Feb. 2026, 21:34 UTC

Ergebnisse

Ampol Says F&I Australia, International Have Begun 2026 Strongly

22. Feb. 2026, 21:34 UTC

Ergebnisse

Ampol Expects Stage 1 of Fuel Security Services Payment Review Finalized in 1Q

22. Feb. 2026, 21:33 UTC

Ergebnisse

Ampol Says Lytton Refiner Margin Was US$8.13/bbl in January

22. Feb. 2026, 21:33 UTC

Ergebnisse

Ampol Recognizes A$89.9 Million Impairment in Carrying Value of Investment in Seaoil

22. Feb. 2026, 21:28 UTC

Ergebnisse

Ampol Final Dividend A$0.60/Share

22. Feb. 2026, 21:28 UTC

Ergebnisse

Ampol FY Revenue A$31.37 Billion, Down 10%

22. Feb. 2026, 21:28 UTC

Ergebnisse

Ampol FY Replacement-Cost Net Profit A$429.2 Million, Up 83%

22. Feb. 2026, 21:28 UTC

Ergebnisse

Ampol FY Historical-Cost Net Profit A$82.4 Million, Down 33%

21. Feb. 2026, 14:31 UTC

Akquisitionen, Fusionen, Übernahmen

Bridgewater Associates' 4Q Buying and Selling -- Barrons.com

21. Feb. 2026, 05:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

20. Feb. 2026, 23:12 UTC

Akquisitionen, Fusionen, Übernahmen

FERC Authorizes TXNM Energy Acquisition by Blackstone Infrastructure

20. Feb. 2026, 22:12 UTC

Ergebnisse

Equinox Gold: Announces Filing of 2025 Audited Fincl Statements

20. Feb. 2026, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

20. Feb. 2026, 21:50 UTC

Market Talk

Auto & Transport Roundup: Market Talk

20. Feb. 2026, 21:23 UTC

Ergebnisse

These Stocks Are Today's Movers: Grail, Corning, Comfort Systems USA, Opendoor, Akamai, Chemours, and More -- Barrons.com

20. Feb. 2026, 21:20 UTC

Market Talk

Century Aluminum Backs Trump's Tariffs After SCOTUS Ruling -- Market Talk

20. Feb. 2026, 21:01 UTC

Akquisitionen, Fusionen, Übernahmen

Want to Win the Warner Bros. Discovery Takeover Battle? 'Walk Away Now.' -- Barrons.com

20. Feb. 2026, 20:38 UTC

Market Talk

U.S. Natural Gas Gains Ahead of Chilly Weekend -- Market Talk

Peer-Vergleich

Kursveränderung

Pliant Therapeutics Inc Prognose

Rating-Konsens

By TipRanks

Sell

1 ratings

Buy

Halten

Sell

Basierend auf 1 Analysten, die in den letzten 3 Monaten Aktienbewertungen für Pliant Therapeutics Inc – Dist abgegeben haben.

Technischer Score

By Trading Central

1.43 / 1.6Unterstützung & Widerstand

Recent bearish events outweigh bullish events.

There is one bearish event.

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

Über Pliant Therapeutics Inc

Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. The company's lead candidate is bexotegrast, an oral, small-molecule, dual selective inhibitor of avß6 and avß1 integrins, which is in phase 2b trials for idiopathic pulmonary fibrosis and in phase 2a trial for primary sclerosing cholangitis. It also develops PLN-1474, an oral, small-molecule selective inhibitor of avß1 for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis; PLN-101095, a dual inhibitor of integrins avß8 and avß1 for the treatment of solid tumors; and PLN-101325 for treatment of muscular dystrophies. Pliant Therapeutics, Inc. was incorporated in 2015 and is based in South San Francisco, California.